Photo from academic.microsoft.com
A randomized, open-label phase III trial of custirsen in 635 men with metastatic castration-resistant prostate cancer that had progressed after docetaxel showed no survival benefit for the addition of custirsen… Click to show full abstract
A randomized, open-label phase III trial of custirsen in 635 men with metastatic castration-resistant prostate cancer that had progressed after docetaxel showed no survival benefit for the addition of custirsen to cabazitaxel plus prednisone treatment. The antisense oligonucleotide custirsen inhibits the production of the antiapoptotic protein clusterin, which is upregulated in response to chemotherapy and confers treatment resistance. Median overall survival in the custirsen and control groups was 14.1 months and 13.4 months, respectively.
Journal Title: Nature Reviews Urology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!